Soolantra Cream 1% is a branded formulation of topical ivermectin designed specifically for papulopustular rosacea. It combines anti-inflammatory and anti-Demodex activity, helping reduce redness, irritation, and inflammatory lesions with minimal systemic absorption. As a topical therapy, Soolantra acts directly on affected skin areas, offering targeted relief without the systemic effects associated with oral ivermectin.
Compared with generic ivermectin cream 1%, Soolantra features a proprietary formulation that may differ in texture, spreadability, and inactive ingredients, while delivering the same active ingredient concentration. This guide explains how Soolantra compares with generic ivermectin, what side effects to expect, and what influences its price — helping you decide where to buy Soolantra safely. Explore related sections: Ivermectin topical, Ivermectin cream 1%, Soolantra vs Ivermectin.
Soolantra Cream 1% is a branded topical medication developed by Galderma, formulated specifically for inflammatory facial dermatoses such as papulopustular rosacea. Its active ingredient is ivermectin 1%, a compound with dual anti‑inflammatory and anti‑Demodex activity. Soolantra is widely recognized for its high tolerability, cosmetic elegance, and strong clinical evidence supporting its use in rosacea and related conditions.
The formulation is designed as a soft, dermatologically adapted cream, offering a smooth, non‑greasy texture that spreads easily across sensitive or inflamed skin. This cream‑based vehicle is one of the key differentiators between Soolantra and generic ivermectin products, which may also be available as lotions or gels. The cream format provides superior hydration, reduces irritation, and supports the skin barrier—an essential factor for rosacea‑prone patients.
Galderma is a global dermatology company known for developing prescription and cosmetic dermatology products. Soolantra is part of its rosacea‑focused portfolio and has undergone extensive clinical testing to ensure efficacy and tolerability.
Soolantra contains ivermectin 1%, the standard concentration used in topical formulations for rosacea. This strength provides effective anti‑inflammatory action while minimizing irritation.
The cream base is rich yet lightweight, designed to:
Unlike lotion or gel formulations of generic ivermectin:
Soolantra’s cream vehicle is considered the most tolerable option, especially for rosacea.
| Parameter | Value |
|---|---|
| Brand | Galderma |
| Active ingredient | Ivermectin 1% |
| Texture | Soft, dermatology‑optimized cream |
| Difference from lotion/gel | More hydrating; best tolerability |
Soolantra Cream 1% combines the pharmacologic properties of ivermectin with a dermatology‑optimized cream vehicle, resulting in a dual‑action mechanism highly effective for papulopustular rosacea. Its MOA includes anti‑Demodex activity, anti‑inflammatory effects, and reduction of papulopustular lesions. Mechanistic details of ivermectin are discussed in Ivermectin MOA.
Ivermectin binds to glutamate‑gated chloride channels in Demodex folliculorum, causing paralysis and death of the mites. Because Demodex density is elevated in rosacea, reducing mite populations decreases follicular inflammation and improves skin texture.
Soolantra suppresses inflammatory mediators such as IL‑8, TNF‑α, and TLR‑2. This reduces erythema, swelling, and discomfort associated with rosacea. The cream vehicle enhances tolerability, allowing consistent anti‑inflammatory action without significant irritation.
By targeting both mites and inflammatory pathways, Soolantra significantly reduces papules and pustules. Clinical trials show rapid improvement within weeks, with continued reduction over long‑term use.
Unlike oral ivermectin, which acts systemically through broad antiparasitic pathways, Soolantra acts locally within the epidermis and follicles. This localized MOA minimizes systemic exposure and side effects.
| MOA element | Description |
|---|---|
| Anti‑Demodex | Paralysis and elimination of mites |
| Anti‑inflammatory | Reduces IL‑8, TNF‑α, TLR‑2 activity |
| Lesion reduction | Decreases papules and pustules |
| Local vs systemic | Acts locally; minimal systemic involvement |
The pharmacokinetic profile of Soolantra reflects its design as a topical, locally acting formulation. Its PK behavior ensures strong epidermal activity with minimal systemic exposure. More details on ivermectin PK are available at Ivermectin PK.
Clinical PK studies show that Soolantra produces negligible plasma concentrations, far below those associated with oral ivermectin. This minimizes systemic side effects and drug interactions.
After application, ivermectin accumulates in the stratum corneum and pilosebaceous units, where Demodex mites reside. The cream vehicle enhances uniform distribution and sustained local activity.
Because systemic absorption is minimal, Soolantra does not meaningfully interact with CYP3A4 substrates, P‑gp modulators, or other systemic medications.
Oral ivermectin undergoes GI absorption, hepatic metabolism, and systemic distribution. Soolantra bypasses these pathways entirely, acting only within the skin.
| PK parameter | Value |
|---|---|
| Systemic absorption | Minimal; negligible plasma levels |
| Epidermal distribution | High concentration in follicles |
| Drug interactions | No clinically relevant interactions |
| Oral vs topical PK | Topical acts locally; oral acts systemically |
Soolantra Cream 1% is a prescription topical therapy designed primarily for inflammatory facial dermatoses, with its strongest evidence base in papulopustular rosacea. Its dual anti‑Demodex and anti‑inflammatory activity makes it effective across several related conditions, including off‑label uses. Mechanistic and clinical details are discussed in Ivermectin for rosacea, Ivermectin for demodex, Ivermectin for acne, Ivermectin for perioral dermatitis.
Soolantra is FDA‑approved for papulopustular rosacea, the inflammatory subtype characterized by papules, pustules, and background erythema. Its efficacy is driven by:
Clinical trials demonstrate significant lesion reduction within 2–4 weeks, with continued improvement over 12–16 weeks. Soolantra is particularly effective in Demodex‑associated rosacea, where mite overgrowth contributes to inflammation.
Because ivermectin directly targets Demodex folliculorum, Soolantra is highly effective in reducing mite density. This leads to:
It is often preferred over permethrin due to superior tolerability.
Soolantra may be used off‑label for inflammatory acne, particularly when Demodex involvement is suspected. It helps reduce:
It is not comedolytic, so it is typically combined with non‑irritating acne therapies.
Soolantra is increasingly used off‑label for perioral dermatitis, especially in steroid‑induced or rosacea‑like variants. Benefits include:
| Condition | Clinical role | Notes |
|---|---|---|
| Papulopustular rosacea | Primary indication | Strong clinical evidence; anti‑Demodex + anti‑inflammatory |
| Demodex infestation | High efficacy | Reduces mite density; improves inflammation |
| Acne (off‑label) | Adjunctive role | Useful for inflammatory lesions; not comedolytic |
| Perioral dermatitis (off‑label) | Alternative therapy | Good tolerability; reduces sensitivity |
Soolantra Cream 1% contains the active ingredient ivermectin 1%, supported by a dermatology‑optimized vehicle designed by Galderma to maximize tolerability, hydration, and cosmetic elegance. The formulation differs significantly from many generic ivermectin creams, which may use simpler or more drying excipient systems.
The active component provides anti‑Demodex and anti‑inflammatory effects. The 1% concentration is standard for topical ivermectin and is clinically validated for rosacea.
Soolantra includes a rich blend of emollients that soften the skin, reduce dryness, and support the barrier. These components help minimize irritation, making Soolantra suitable for sensitive and rosacea‑prone skin.
The cream contains stabilizing agents that maintain formulation consistency, enhance shelf stability, and ensure uniform distribution of ivermectin across the skin.
Generic ivermectin creams may contain fewer emollients, lighter emulsifiers, or alcohol‑based components, which can increase dryness or stinging. Soolantra’s premium vehicle is a major reason for its superior tolerability.
| Component | Soolantra | Generic ivermectin cream |
|---|---|---|
| Active ingredient | Ivermectin 1% | Ivermectin 1% |
| Emollients | Rich, barrier‑supportive | Variable; often lighter |
| Stabilizers | Dermatology‑optimized | Standard cosmetic stabilizers |
| Texture | Soft, hydrating cream | May be thicker or less elegant |
Soolantra and generic ivermectin creams share the same active ingredient—ivermectin 1%—but differ substantially in formulation quality, tolerability, cosmetic feel, and clinical validation. A detailed comparison is available at Soolantra vs Ivermectin.
Soolantra uses a premium emollient‑rich vehicle designed to minimize irritation and support the skin barrier. Generic creams may use simpler emulsions, which can be less hydrating and occasionally more irritating.
Clinical trials show Soolantra has very low irritation rates, even in rosacea‑prone skin. Generics are generally well tolerated but may cause more dryness or stinging depending on excipients.
Soolantra has a smooth, elegant, non‑greasy cream texture. Generic creams vary widely—some are thicker, others lighter, and some may lack the same cosmetic elegance.
Soolantra has extensive clinical evidence supporting its efficacy in papulopustular rosacea. Generic ivermectin creams rely on data from the active ingredient rather than full formulation studies.
Soolantra is preferred for its soft feel, easy spreadability, and low irritation. Generics may be more affordable but can differ in comfort and finish.
| Parameter | Soolantra | Generic ivermectin cream |
|---|---|---|
| Composition | Premium emollient‑rich vehicle | Variable; may be less hydrating |
| Tolerability | Very high; minimal irritation | Good; depends on excipients |
| Texture | Soft, elegant cream | Varies; may be thicker or less smooth |
| Clinical data | Extensive rosacea trials | Limited formulation‑specific data |
| Cosmetic acceptability | High; preferred by sensitive skin | Moderate; varies by brand |
Soolantra Cream 1% demonstrates high clinical efficacy in treating papulopustular rosacea due to its dual anti‑Demodex and anti‑inflammatory mechanisms. Multiple randomized controlled trials confirm its ability to reduce inflammatory lesions, improve skin quality, and maintain long‑term remission.
Large‑scale Phase III trials show that Soolantra significantly reduces papules and pustules within the first 2–4 weeks, with continued improvement through 12–16 weeks. Patients treated with Soolantra achieved higher Investigator Global Assessment (IGA) success rates compared with vehicle controls.
Soolantra reduces inflammatory lesions by targeting both Demodex mites and inflammatory mediators. Studies report:
Patients report smoother skin texture, reduced sensitivity, and improved barrier function. The cream vehicle enhances hydration, contributing to better cosmetic outcomes.
Long‑term studies show sustained improvement with continuous use. Many patients maintain remission with ongoing once‑daily application.
| Parameter | Outcome |
|---|---|
| Lesion reduction | Significant decrease within 2–4 weeks |
| Skin quality | Smoother texture, reduced sensitivity |
| Long‑term effect | Sustained remission with continued use |
| Clinical evidence | Strong Phase III trial support |
Soolantra and metronidazole are both established treatments for papulopustular rosacea, but they differ in mechanism, tolerability, speed of action, and clinical outcomes. A detailed comparison is available at Ivermectin vs Metronidazole.
Soolantra combines anti‑Demodex and anti‑inflammatory effects, while metronidazole primarily provides anti‑inflammatory and antimicrobial activity. Soolantra’s ability to reduce Demodex density gives it an advantage in Demodex‑associated rosacea.
Soolantra’s emollient vehicle offers superior tolerability, especially for sensitive skin. Metronidazole is generally well tolerated but may cause mild dryness or stinging, particularly in gel formulations.
Head‑to‑head studies show that Soolantra achieves greater reductions in inflammatory lesions and higher patient satisfaction scores. Metronidazole remains effective but typically shows slower and less pronounced improvement.
Soolantra often produces visible improvement within 2–4 weeks, whereas metronidazole may require 6–8 weeks for comparable results.
| Parameter | Soolantra | Metronidazole |
|---|---|---|
| Mechanism | Anti‑Demodex + anti‑inflammatory | Anti‑inflammatory + antimicrobial |
| Tolerability | Very high; minimal irritation | Good; mild dryness possible |
| Clinical efficacy | Stronger lesion reduction | Moderate improvement |
| Speed of action | 2–4 weeks | 6–8 weeks |
Soolantra Cream 1% and azelaic acid (15–20%) are both widely used for inflammatory facial dermatoses, especially papulopustular rosacea. However, they differ significantly in efficacy, tolerability, skin‑type suitability, and clinical scenarios. A detailed mechanistic comparison is available at Ivermectin vs Azelaic acid.
Soolantra demonstrates strong efficacy due to its dual anti‑Demodex and anti‑inflammatory action. Clinical trials show rapid reduction of papules and pustules within 2–4 weeks. Azelaic acid is effective for inflammatory lesions and erythema but typically works more slowly and may be less effective in Demodex‑associated rosacea.
Soolantra is generally better tolerated thanks to its emollient cream vehicle. Most patients experience minimal dryness or burning. Azelaic acid, by contrast, is known for causing stinging, burning, peeling, and erythema—especially in sensitive or rosacea‑prone skin.
Soolantra is preferred in Demodex‑associated rosacea, papulopustular flares, and cases with significant sensitivity. Azelaic acid is useful when additional keratolytic or pigment‑modulating effects are desired, such as in post‑inflammatory erythema or mild acne‑rosacea overlap.
| Parameter | Soolantra | Azelaic acid |
|---|---|---|
| Efficacy | Strong, fast lesion reduction | Moderate, slower onset |
| Tolerability | Very high; minimal irritation | Lower; frequent burning/stinging |
| Skin type | Sensitive, dry, reactive | Oily, combination |
| Clinical scenarios | Demodex‑associated rosacea | PIE, mild acne‑rosacea |
Soolantra is considered one of the most tolerable topical treatments for rosacea due to its emollient vehicle and minimal systemic absorption. Most adverse reactions are mild, transient, and localized to the application site. A broader overview of ivermectin tolerability is available at Ivermectin topical — side effects.
Common local side effects include:
These reactions typically occur during the first 1–2 weeks and diminish as the skin adapts.
Because Soolantra has negligible systemic absorption, it does not cause systemic side effects or interact with systemic medications. Plasma levels remain far below those associated with oral ivermectin.
Oral ivermectin undergoes systemic distribution and may cause neurological or systemic adverse effects in rare cases. Soolantra avoids these risks entirely due to its localized action within the epidermis and follicles.
| Side effect | Description |
|---|---|
| Local irritation | Mild redness, burning, dryness |
| Systemic effects | None; minimal absorption |
| Difference from oral | No systemic toxicity risk |
Soolantra Cream 1% has an extremely low risk of drug interactions due to its minimal systemic absorption. Pharmacokinetic studies show that ivermectin levels in plasma remain negligible after topical application, meaning the medication acts almost exclusively within the epidermis and pilosebaceous units. As a result, Soolantra does not meaningfully interact with systemic medications, including CYP3A4 substrates, anticoagulants, immunosuppressants, or P‑gp modulators. More details on systemic interaction pathways are discussed in Ivermectin oral interactions.
Because Soolantra does not enter systemic circulation in clinically relevant amounts, it avoids the metabolic pathways responsible for drug–drug interactions. This makes it safe for patients taking multiple medications.
Oral ivermectin undergoes hepatic metabolism and interacts with CYP3A4 and P‑gp pathways, which may lead to systemic adverse effects or interactions. Soolantra bypasses these pathways entirely, offering a significantly safer interaction profile.
The cost of Soolantra Cream 1% varies depending on region, pharmacy, insurance coverage, and packaging volume. As a branded dermatology product developed by Galderma, Soolantra is typically priced higher than generic ivermectin creams. Pricing details can be found at Soolantra price and Ivermectin price.
Soolantra is positioned as a premium rosacea treatment. Its higher cost reflects:
Generic ivermectin creams are significantly more affordable and available in multiple textures (cream, lotion, gel). However, they may differ in tolerability, cosmetic elegance, and consistency of excipients. Many patients choose Soolantra for its superior comfort and lower irritation risk.
Several variables influence the final price:
| Product | Typical price range | Notes |
|---|---|---|
| Soolantra | Higher price tier | Premium vehicle; strong clinical evidence |
| Generic ivermectin | Lower price tier | Varies by formulation and manufacturer |